Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Millenium's genetic maps of disease

Millenium's genetic maps of disease

Millenium Inc. plans to understand disease from the inside out by isolating disease-related genes. But unlike gene therapy companies, it will use the knowledge of those genes to develop a variety of therapeutics, ranging from protein replacement to small molecules.

"Over the past 15 years, companies have

Read the full 510 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers